ArticleChemical science2026
Direct access to 2-imidazolines from unactivated alkenes.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The formation of carbon-nitrogen bonds is crucial for the discovery of pharmaceuticals, materials, and agrochemicals. Nitrogen-containing functional groups, especially heterocycles, are common motifs in biologically active compounds. Among these, 2-imidazolines have emerged as important scaffolds with their own class of biological targets. Herein, we report the development of an oxidative amination process to directly convert unactivated alkenes into 2-imidazolines. The combination of ammonia and a commercially available hypervalent iodine reagent achieves the cleavage of the carbon-carbon double bond. Subsequent interception of the resulting imine by ethylenediamine and oxidation furnishes 2-imidazolines in high yields. The reaction is rapid and tolerates a wide range of functional groups, showcasing its potential for late-stage diversification of complex molecules.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.